Hormonal
Activation of PPARγ (via agonists like TZDs or endogenous upregulation) improves insulin resistance and metabolic homeostasis by enhancing adipose tissue expandability, reducing ectopic lipid accumulation, and promoting browning, rather than solely by reducing fat mass.
Focus on improving the health and capacity of your fat tissue rather than just trying to lose weight. Strategies that support healthy adipose tissue function (like those mediated by PPARs, e.g., through specific medications or lifestyle factors that promote adipogenesis and browning) can improve insulin sensitivity even if body weight remains stable or increases slightly. The key is preventing fat from accumulating in organs like the liver and muscles.
Restoration/maintenance of PPARγ functionality senses the lipid load and enables the recovery of the homeostasis of essential metabolic pathways... The result of pharmacological intervention in obesity with TZDs is the improvement of insulin sensitivity derived from the effects of TZDs improving adipose tissue function despite the associated increase in fat mass.
Why this rating
The paper is a review summarizing multiple studies (mouse models, human patients, clinical trials of TZDs), providing strong mechanistic evidence but lacking a single large-scale RCT in the text itself.
Source
PPARs and Metabolic Disorders Associated with Challenged Adipose Tissue Plasticity
Patricia Corrales et al. · International Journal of Molecular Sciences · 2018
DOI 10.3390/ijms19072124
More from this paper
- PPARα activation promotes fatty acid oxidation and energy expenditure, particularly in the liver and brown adipose tissue, contributing to the treatment of hypertriglyceridemia and obesity-induced insulin resistance.Moderate
- PPARβ/δ activation reduces systemic inflammation and promotes fatty acid oxidation in skeletal muscle and brown adipose tissue, offering potential therapeutic benefits for obesity and insulin resistance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →